Sodium ions are endogenous allosteric modulators of many G-protein-coupled receptors (GPCRs). Mutation of key residues in the sodium binding motif causes a striking effect on G-protein signaling. We report the crystal structures of agonist complexes for two variants in the first sodium coordination shell of the human A 2A adenosine receptor, D52
In Brief White and Eddy et al. report agonistbound structures of human A 2A AR variants that disrupt allosteric sodium effects. The structures reveal changes in hydrogen bonding near a conserved activation motif that correspond to striking differences in signaling, providing a rationale for increased variant receptor stability. (Changeux and Christopoulos, 2016; van der Westhuizen et al., 2015) . In particular, sodium ions have been proposed to be an endogenous allosteric modulator for many GPCRs . Observations in mouse brain extracts over 40 years ago first demonstrated the allosteric effects of sodium on opioid receptors (Pert et al., 1973) . Since those initial observations, sodium's allosteric effects have been reported from in vitro and in vivo assays for over 15 GPCRs, including adrenergic receptors (Ceresa and Limbird, 1994), adenosine receptors (Gutié rrez-deTerá n et al., 2013), dopamine receptors (Neve, 1991) , and others as reviewed in the literature . Allosteric effects of sodium have been found to be largely mediated by the negatively charged residue D 2.50 (Ceresa and Limbird, 1994; Fenalti et al., 2014; Katritch et al., 2014; Liu et al., 2012; Massink et al., 2015; Werling et al., 1986 ) located in transmembrane helix II (superscripts indicate the Ballesteros-Weinstein nomenclature; Ballesteros and Weinstein, 1995) . D 2.50 is one of the most highly conserved amino acids in class A GPCRs . Replacement of D 2.50 with a neutral amino acid diminished the ability of sodium to compete with agonist binding and concurrently affected G-protein signaling for more than 25 different GPCRs (Hishinuma et al., 2017; Katritch et al., 2014) . In the d-opioid receptor (DOR), a D 2.50 variant switched the efficacy of an antagonist to an arrestinbiased agonist . For the human A 2A adenosine receptor (A 2A AR), replacement of D 2.50 with alanine completely abolished G-protein-dependent signaling (Massink et al., 2015) . D 2.50 forms the core of a cluster of residues that coordinate a sodium ion that was first observed in a high-resolution crystal structure of A 2A AR in complex with an antagonist and subsequently observed in a DOR-antagonist complex . In those structures, other residues coordinating sodium are S 3.39 , which also directly coordinates sodium, and W 6.48 , N 7.49 , N 7.45 , and S 7.46 , which indirectly coordinate sodium through a network of water molecules ( Figure 1 ). All of these sodium-coordinating residues are highly conserved among class A GPCRs . In A 2A AR, replacement of any of these sodium pocket residues with alanine altered agonistinduced G-protein signaling (Massink et al., 2015) . Sodium-coordinating residues also strongly influence thermal unfolding temperatures of GPCRs. Replacement of one or more of the sodium-coordinating residues increased denaturation temperatures for several GPCRs, including the neurotensin receptor (NTSR1) (Shibata et al., 2009) , k-opioid receptor (KOR) (Schutz et al., 2016) , and a 1a adrenergic receptor (Dodevski and Pluckthun, 2011) . For the purinergic P2Y 1 receptor (P2Y 1 R), replacement of an endogenous D 7.49 with asparagine improved protein expression yield and was required for crystallization of a P2Y 1 R-antagonist complexes (Zhang et al., 2015a) . Recently, observations in A 2A AR by nuclear magnetic resonance (NMR) spectroscopy showed that replacement of D 2.50 with asparagine drastically altered conformational dynamics at the A 2A AR intracellular surface without altering the receptor's conformation at the extracellular surface (Eddy et al., 2017) . Motivated by these numerous observations, we sought to provide a structural basis for how the sodium-coordinating residues regulate G-protein signaling and affect denaturation temperatures of human A 2A AR. A 2A AR is a validated drug target for Parkinson's disease (Cie slak et al., 2008) and chronic obstructive pulmonary disease (Bonneau et al., 2006) and a promising target for cancer co-immunotherapies (Leone et al., 2015) . Thus, the role of the allosteric sodium site in A 2A AR drug discovery is of relevant interest. We determined crystal structures of A 2A AR variants D 2.50 N and S 3.39 A in complex with the full agonist UK432097 at 2.6 and 2.9 Å resolution, respectively ( Figure 2) . Comparison of the structures was complemented by protein thermal stability and cAMP signaling assays, which showed significant differences among the A 2A AR variants. As the residues comprising the allosteric sodium pocket are highly conserved, these data likely provide fresh insights into regulation of G-protein signaling by allosteric sodium-coordinating residues for many class A GPCRs and provide new tools for GPCR drug discovery. Our results suggest utility for the D 2.50 N variant as an exciting approach for accelerated crystallization and drugscreening efforts for class A GPCRs.
RESULTS

Functional Characterization of A 2A AR Sodium-Site Variants
In the high-resolution crystal structure of antagonist-bound A 2A AR, D52
2.50 and S91 3.39 were the only two residues observed to directly coordinate the sodium ion ( Figure 1 ) (Massink et al., 2015) , while A 2A ARÀS91A had similar activity to A 2A AR ( Figure 2B and Table 1 ). While A 2A ARÀS91A signaling was previously found to have higher basal and lower E max signaling upon CGS21680 agonist stimulation (Massink et al., 2015) , differences reported here may be due to using different cell types, agonists, and assay conditions (for example, adenosine deaminase was included in our experiments to eliminate the influence of endogenous adenosine).
Crystal Structures of A 2A AR Sodium-Site Variants in Complex with an Agonist Present an Overall Active-like Conformation We determined the crystal structures of A 2A ARÀD52N and A 2A ARÀS91A in complex with the full agonist UK432097. To compare these structures with the previously published crystal structure of A 2A AR in complex with the agonist UK432097 (A 2A ARÀUK432097; PDB: 3QAK) , we employed a nearly identical construct, where the A 2A AR third intracellular loop (ICL3) was replaced with T4 lysozyme (T4L) to facilitate crystallization . The only change effected to this earlier construct was the single amino acid replacement, D52N or S91A. To ensure the crystallization constructs have binding affinities similar to those of A 2A AR and A 2A AR variants without the T4L ICL3 fusion, we determined the affinity of the agonists CGS21680 and UK432097 prior to crystallization. A 2A AR, A 2A ARÀD52NÀT4L, and A 2A ARÀS91AÀT4L all had very similar affinities (K D ) for CGS21680, 13.6 ± 3.1, 12.0 ± 3.6, and 10.0 ± 4.9 nM, respectively ( Table 1) . The agonist UK432097, co-crystallized in complex with each construct, also showed similar affinities (K i ) for A 2A AR, A 2A ARÀD52NÀT4L, and A 2A ARÀS91AÀT4L: 17.3 ± 5.9, 25.2 ± 3.5, and 20.0 ± 3.7 nM, respectively ( Table 1) .
Crystallization of A 2A ARÀD52NÀT4L and A 2A ARÀS91AÀT4L bound to the agonist UK432097 was carried out in lipid cubic phase (LCP) (Caffrey and Cherezov, 2009) (Figure S1 ), and the structures were refined to a final resolution of 2.6 and 2.9 Å , respectively ( Figures 2C-2H were made only for constructs that have this identical T4L fusion partner for consistency and to remove the possibility of introducing bias by using different fusion partners. Throughout the article, we refer to the co-crystal structures of UK432097 bound to A 2A ARÀD52NÀT4L and A 2A ARÀS91AÀT4L as D52NÀUK432097 and S91AÀUK432097, respectively. Comparing the structure of the agonist-bound D52NÀ UK432097 complex with the previously published structures of A 2A ARÀT4L in complex with the antagonist ZM241385 (A 2A ARÀZM241385; PDB: 3EML) and A2 2A ARÀT4L in complex with the agonist UK432097 (A 2A ARÀUK432097; PDB: 3QAK) showed that the overall structure of the variant protein presented hallmarks of an active-like state ( Figures 2C and 2D) . Specifically, the positions of helices at the intracellular surface of the D52NÀUK432097 complex were displaced from the antagonist-bound structure in the same directions expected for an active-like conformation. The alignment of D52NÀUK432097 and A 2A ARÀZM241385 was performed after removal of fusion partner atoms and the root-mean-square deviation (RMSD) was 1.33 Å (264 aligned Ca atoms). an overall strong agreement between the two structures with an RMSD of 0.32 Å (263 aligned Ca atoms). Residues in the ligand binding pocket and the binding pose of UK432097 appeared to be nearly identical between A 2A ARÀUK432097 and D52NÀUK432097 agonist complexes (Figures 2D, S2A, and S2B) , indicating the D52N replacement did not interfere with the conformation of the agonist in the binding pocket. We also solved a crystal structure of the variant A 2A ARÀS91A in complex with the agonist UK432097 using the same T4L fusion construct design, referred to as S91AÀUK432097. Crystallization of S91AÀUK432097 was also performed in LCP (Caffrey and Cherezov, 2009) and the structure was refined to 2.9 Å . The S91AÀUK432097 also showed active-like features that were very similar to both D52NÀUK432097 (RMSD 0.44 Å , 263 aligned Ca atoms) ( Figure 2E and Table 2) Residues in the NPxxY Motif of D52N-UK432097 Are Neither in an Entirely Inactive Nor an Active-like Conformation The relative side-chain orientations in GPCR microswitches are sensitive to differences of the pharmacological efficacies of bound ligands . Rearrangements in side chains of the microswitches are thought to precede larger structural rearrangements of helical backbones required for the receptor to recognize intracellular partner proteins. We compared the structures of antagonist-bound A 2A ARÀZM241385 (PDB: 3EML), agonist-bound A 2A ARÀUK432097 (PDB: 3QAK), and agonist-bound D52N-UK432097 in four conserved structural motifs: the PIF motif formed between helices III, V, and VI; the CWxP motif in helix VI; the DRY motif in helix III; and the NPxxY motif in helix VII ( Figure 3 ). Strong electron densities in the microswitch regions of D52NÀUK432097 ( Figure S2C ) allowed us to confidently compare backbone and side-chain orientations for residues in these regions. We observed strong overlap between A 2A ARÀUK432097 and D52NÀUK432097 for three microswitch regions: PIF, CWxP, and DRY. Because there was strong agreement in these regions between A 2A ARÀUK432097 and D52N-UK432097 ( Figures 3A-3C ), we concluded that sidechain orientations for D52NÀUK432097 were in an active-like conformation.
Comparing the RMSD in the positions of Ca atoms between the structures of A 2A ARÀUK432097 and D52NÀUK432097 revealed that the largest differences occurred for residues in the NPxxY motif in helix VII and for residues immediately preceding this motif ( Figure 4A ). The structural rearrangement begins at S281 7.46 , which has an altered Ca position in D52NÀUK432097 relative to A 2A ARÀUK432097 of 2.4 Å . Furthermore, the Ca positions for several subsequent residues are also altered: V282 ARÀUK432097 and D52NÀ UK432097, that extends through the conformations of the remaining residues from the intracellular surface to the C terminus ( Figure 4A ).
The structural rearrangement near the NPxxY motif of D52NÀUK432097 was observed in the difference electrondensity maps (jF o j À jF c j) between D52NÀUK432097 and A 2A ARÀUK432097 ( Figure S2E ). The difference electron-density maps show clear rearrangements near S281 7.46 , P285 7.50 , and the site of mutation N52 2.50 ( Figure S2E ). Similar differences were observed in the jF o j À jF c j maps using the molecular replacement solution with A 2A ARÀUK432097 as a search model. We observed negative electron densities at S281
7.46 and positive , consistent with our final D52NÀUK432097 structure ( Figure S2F ). In addition, we solved the structure of D52NÀUK432097 using A 2A ARÀUK432097 or A 2A ARÀZM241385 as search models and obtained the same results, confirming that the structural rearrangements near the NPxxY motif are not due to phase bias.
The two most significant differences between the D52NÀ UK432097 and the S91AÀUK432097 structures is the rotamer position of S281 7.46 as well as differences in Ca position of residues in the NPxxY motif ( Figures S2A-S2D ). Because the electron-density maps were more ambiguous in the NPxxY motif for the S91AÀUK432097 structure ( Figures S2C and S2D . This dye produces a signal when it conjugates to cysteine residues buried in the receptor transmembrane helices that become exposed to an aqueous environment upon heating the protein (Alexandrov et al., 2008) .
To investigate the effect of the sodium allosteric site on receptor melting temperatures, we included five A 2A AR variants in the thermal denaturation experiments. Purified A 2A ARÀBRIL reconstituted into n-dodecyl b-D-maltoside (DDM)/cholesteryl hemisuccinate (CHS) mixed micelles was added to a panel of ligands at saturating concentrations (25 mM for UK432097 and 100 mM for all other ligands) or no ligand added (apo) all in the presence of 150 mM NaCl. In these conditions, A 2A ARÀD52N showed the highest denaturation temperature for all but one ligand complex (A 2A ARÀN284A in complex with UK432097 showed the overall highest T m of nearly 75 C) ( Table S1 ). The most striking effect was for apo A 2A ARÀD52N, which showed a nearly 8 C increase in the T m compared with apo A 2A AR ( Figure 6A) . Notably, for the variant A 2A ARÀD52A, we observed a melting temperature that was slightly lower than for A 2A AR and markedly lower than for A 2A ARÀD52N for all ligands studied. This striking difference can be rationalized by the loss of hydrogen bonds in A 2A ARÀD52A, which are observed in A 2A ARÀD52N between N52 2.50 and residues in helices II, III, and VII (Figures 5 and S3 ). The measured T m values for Figure 6A are given in Table S1 .
There was a statistically significant difference in T m between receptor variants for each ligand condition tested as determined by one-way ANOVA: apo (F (5,17) = 14.18, p < 0. In addition, we recorded thermal denaturation experiments for A 2A AR in complex with a larger selection of ligands at a lower sodium concentration of 75 mM ( Figure 6B ) and in the absence and presence of sodium at variable concentrations ( Figure 6C ) to investigate the effect of different sodium concentrations on receptor stability. At 75 mM NaCl, the highest melting temperatures were observed for complexes with either full or partial agonists, which were 6 C to 10 C higher than melting temperatures reported for A 2A AR in complex with the same or similar agonists and partial agonists in the presence of 800 mM NaCl . Melting temperatures for A 2A AR in complex with antagonists were similar to previously reported melting temperatures for A 2A AR antagonist complexes in the presence of 800 mM NaCl Xu et al., 2011) . Experiments using variable sodium concentrations confirmed the sensitivity of agonist complexes to sodium and indicated a greater effect of sodium on agonist complexes than on antagonist complexes. The melting temperatures of A 2A AR in complex with the full agonist UK432097 were 77.7 C, 73.2 C, and 69.7 C at 0, 150, and 500 mM NaCl, respectively ( Figure 6C ). This effect was not observed when using 150 or 500 mM choline chloride ( Figure S6 ). This trend of sodium on A 2A AR melting temperatures may reflect changes in rates of ligand association or dissociation specific to agonist complexes (see Discussion).
DISCUSSION
The combination of structural, biophysical, and pharmacological data presented here provides a basis to delineate the role of the D 2.50 N mutation on A 2A AR thermal stability, the structure of the NPxxY activation motif, and inhibition of G-protein signaling. In addition, the D 2.50 N mutation desensitizes the response of A 2A AR agonist binding to increasing sodium concentration, which has been documented in other receptors including DOR . We propose that this sodium desensitization and loss of G-protein signaling are manifested by D 2.50 N, and that loss of G-protein signaling is due to subtle changes in interhelical packing facilitated by specific interactions with N 2.50 .
Local conformational changes observed in the NPxxY motif for D52NÀUK432097 suggest coupling between the NPxxY motif and position D 2.50 that may contribute to changes in signaling for the variant protein. It has been proposed that maintaining the structural integrity of the NPxxY motif in native class A receptors is critical for signal propagation from the orthosteric ligand binding site to the intracellular surface (Fritze et al., 2003; Hulme, 2013; Trzaskowski et al., 2012) . In earlier studies, replacement of residues in the NPxxY motif resulted in apparent attenuation or complete loss of G-protein signaling (Borroto-Escuela et al., 2011; Bouley et al., 2003; Galé s et al., 2000; Govaerts et al., 2001; Lu et al., 2001; Raitio et al., 2005) . Replacement of N 7.49
with alanine did not significantly perturb ligand binding affinities but caused a striking loss of G-protein signaling for a number of receptors. In the CB2 cannabinoid receptor, replacement of S 7.46 with alanine causes of loss of agonist-induced signaling for some ligands (Raitio et al., 2005) . Thus, differences in signaling for the D52NÀUK432097 complex and local structural rearrangements in the NPxxY motif and residues immediately preceding appear consistent with mutational studies that disrupted the same region. It has been proposed that the NPxxY region facilitates signaling through changes in the network of hydrogenbonded water molecules (Pardo et al., 2007) , which may rationalize the required structural integrity of this region.
Comparison of the agonist-bound variant D52NÀUK432097 crystal structure with the crystal structures of A 2A ARÀUK432097 (PDB: 3QAK) and A 2A ARÀZM241385 (PDB: 3EML) provides fresh insight into the mechanism of how agonist binding at the orthosteric ligand cavity leads to conformational changes and interactions of helices that lead to receptor activation. Starting at Table S1 , and statistical analysis is shown in Figure S5 . the orthosteric binding pocket, the ribose moiety of agonist UK432097 makes unique contacts with S277 7. 42 and H278 7.43 in helix VII. As this ribose moiety is characteristic of all A 2A AR full agonists, structures of A 2A AR in complex with other agonists also revealed the same critical contacts between the agonists and helix VII (Lebon et al., 2011b) . While important agonist-receptor interactions occur at helix VII, a recent structure of an A 2A AR ternary complex with an agonist, NECA, and engineered G protein revealed a larger outward rearrangement of helix VI at the intracellular surface (Carpenter et al., 2016) . From these observations, we propose that a key step in signal propagation from the orthosteric site involves interactions between helices VI and VII near the orthosteric pocket and the NPxxY activation motif ( Figures 7A and 7B ). Although additional interactions are likely also involved in activation, these observations are intriguing in the context of analyzing patterns of interaction networks among class A GPCRs (Venkatakrishnan et al., 2013 (Venkatakrishnan et al., , 2016 . For the D52NÀUK432097 agonist complex, loss of interactions between helices VI and VII and concurrent gain of interactions between helices VII and II are correlated with a loss of G-protein signaling and increased thermal stability (Figures 5  and 7D ). In addition, the protonation state of D 2.50 may be involved in A 2A AR signaling, as was suggested by recent analysis of crystal structures of class A GPCR-ligand complexes and computational modeling (Vickery et al., 2018) . This study suggests that for inactive conformations, D 2.50 is negatively charged and forms coordinative bonds with sodium, while agonist binding facilitates D 2.50 protonation and intracellular transfer of sodium.
The schematic in Figure 7 summarizes experimental conditions from the literature and current study and highlights the effects of a spectrum of sodium concentrations on A 2A AR agonist binding. The extreme boundaries of sodium concentrations provide a mechanistic understanding of A 2A AR function that will inform future experimental design ( Figures  7A-7C) . At a lower sodium concentration of 75 mM NaCl, all A 2A AR complexes with either partial or full agonists had a higher melting temperature than almost all antagonist complexes, even for the antagonist ZM241385 that has been co-crystallized with A 2A AR ( Figure 6B ). Furthermore, A 2A AR in complex with UK432097 showed a trend of decreasing melting temperatures with increasing concentration of sodium (150 mM and higher) ( Figure 6C ). Typically, antagonists are thought to have a more stabilizing effect on receptors than agonists Zhang et al., 2015b) , but our data suggest that may be the case only at sodium concentrations higher than physiologically relevant levels (R150 mM NaCl).
From these collective observations, we propose that the collapsed sodium pocket observed in A 2A AR agonist-bound states facilitates stronger helix-helix interactions at the intersection between helices II, III, VI, and VII. Coordination of sodium at this intersection maintains these interactions but decreases their strength. In addition, the coordination of sodium at this site possibly modulates the conformation of the orthosteric pocket in subtle ways that could result in suboptimal interactions between agonists and receptor ( Figure 7C ). The notion of suboptimal agonist-receptor interactions is supported by the observation of decreased ligand binding affinities for agonists, but not antagonists, in the presence of physiological concentrations of sodium (150 mM) Pert et al., 1973) . This was also observed for the agonist NECA binding to A 2A AR, but not for variants A 2A ARÀD52N and A 2A ARÀS91A (Table 1) .
The data reported here suggest an important utility of the D 2.50 N mutation in GPCR construct design for drug discovery and biophysical assays that has not yet been explored fully. The D 2.50 N single-point mutation increases the T m of all A 2A AR ligand complexes, and there is an especially large increase in the T m for the apo receptor ( Figure 6A ). While A 2A ARÀD52N exhibits no G-protein signaling (Figure 2B ), the conformations of residues in the ligand binding pocket and binding pose of the bound agonist are identical to A 2A ARÀUK432097. Also, ligand binding affinities of antagonist ZM241385 and agonist UK432097 were nearly identical between A 2A AR and A 2A ARÀD52N (Table 1) . Because D 2.50 is one of the most highly conserved amino acids among all class A GPCRs , introducing a single-point mutation at this location may provide a rapid and straightforward means for improving the overall stability and expression of many GPCRs and may accelerate the design of GPCR constructs for crystallization trials. Further, this method may also improve efforts for fragment-based screening of small molecules that target GPCRs, for example, by NMR (Chen et al., 2012) or surface plasmon resonance (Shepherd et al., 2014) , because these methods rely on immobilized GPCRs that have relatively higher denaturation temperatures.
Replacement of D 2.50 has been shown to be beneficial to the stabilization of both the KOR and NTSR1 in a recent study utilizing the directed evolution approach of GPCR stabilization (Schutz et al., 2016) . It is notable that the directed evolution approach utilized no prior knowledge about which mutations could potentially be beneficial; however, evolved constructs for both KOR and NTSR1 included substitutions at D 2.50 . Other methods of stabilizing GPCRs, including systematic alanine scanning (Lebon et al., 2011a) or the directed evolution approach (Schutz et al., 2016) , have been essential for structure determination of unique GPCRs. However, such methods can be time and resource consuming and may stabilize receptor interactions with ligands of specific chemical or pharmacological properties, which can limit experimental probing with multiple ligands. Here we propose an alternative approach of a single mutant, D 2.50 N, which significantly boosts receptor stability, increases the melting temperature of apo GPCRs and GPCR-ligand complexes, and maintains ligand binding affinities similar to the native receptor. Thus, utilization of the D 2.50 N mutation across the spectrum of class A GPCRs may improve the robustness of screening platforms and accelerate drug discovery.
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Fluorescent Thermal Shift Assays -CPM Assays Thermal shift assays were carried out as described previously (Alexandrov et al., 2008) . N-[4-(7-diethylamino-4-methyl-3-coumarinyl) phenyl]maleimide (CPM; Invitrogen) was dissolved at 4 mg/ml in dimethylformamide (Sigma) and further diluted at a ratio of 1:1000 v/v in sample buffer that consisted of 50 mM HEPES pH 7.0, 150 mM NaCl, 0.05% DDM, and 0.01% CHS (Figure 6A ), or in the presence of 75 mM NaCl ( Figure 6B ). For studying the effects of sodium on receptor melting temperatures ( Figures 6C  and S6 ), the receptor was purified with KCl instead of NaCl followed by a desalting step to replace KCl with 75 mM choline chloride. These samples were then diluted in assay buffer containing salt conditions specified in the figures (Figures 6C and S6 ). Approximately 5 mg of protein with no ligand added (apo) was incubated on ice with CPM buffer containing ligand in a total volume of 200 mL. Assays were performed with a Cary Eclipse spectrofluorometer using quartz cuvettes (Starna Cells, Inc., Atascadero, CA) over a linear temperature range from 20 C to 90 C heated at a constant rate of 2 C/min. The excitation wavelength was 384 nm, and the emission wavelength was 470 nm.
Signaling Assay -cAMP Assay CHO cells (ATCC) were grown in DMEM and F12 (1:1) supplemented with 10% fetal bovine serum, 100 Units/ml penicillin, 100 mg/ml streptomycin, and 2 mmol/ml glutamine. Transfection of the wild-type or mutant A 2A AR was performed in 6-well plate (0.5 mg plasmids/well) using Lipofectamine 2000. After 48 hours, cells were treated with assay buffer containing rolipram (10 mM) and adenosine deaminase (3 units/ml) for 30 min followed by the addition of agonists and incubated for 20 min. The reaction was terminated upon removal of the supernatant, and addition of 100 ml Tween-20 (0.3%). Intracellular cAMP levels were measured with an ALPHAScreen cAMP assay kit as instructed by the manufacturer (PerkinElmer).
Radioligand Binding Assay HEK293 cells (ATCC) were cultured in DMEM supplemented with 10% fetal bovine serum, 100 Units/ml penicillin, 100 mg/ml streptomycin, and 2 mmol/ml glutamine. Lipofectamine 2000 was used for the transfection of the wild-type or mutant A 2A AR. Transfected cells were detached from plates by scraping into cold PBS and centrifuged at 250 g for 5 min. The pellets were resuspended in icecold Tris HCl buffer (50 mM, pH 7.4) and then homogenized. After homogenization and suspension, cells were centrifuged at 1000 g for 10 min, and the pellet was discarded. The suspension was then re-centrifuged at 20,000 g for 60 min at 4 C. The pellets were resuspended in buffer containing 3 Units/ml adenosine deaminase and incubated at 37 C for 30 min. The aliquots of membrane preparations were stored at -80 C until the binding experiments. The protein concentration was measured using the Bradford assay. For saturation binding, [ 3 H] CGS21680 (ranging from 2 to 100 nM) was incubated with membrane preparations (5-10 mg proteins/tube) for 60 min at 25 C in a total assay volume of 200 mL of 50 mM Tris HCl (pH 7.4) containing 10 mM MgCl 2 . Nonspecific binding was determined using 10 mM NECA. For displacement binding assays, membrane preparations (10-20 mg proteins/tube) were incubated at 25 C for 60 min with a final concentration of 5 nM [ 3 H] CGS21680 in a mixture containing 50 mL of increasing concentrations of a test ligand in a total assay volume of 200 mL of 50 mM Tris HCl, pH 7.4, containing 10 mM MgCl 2 . Nonspecific binding was determined using 10 mM of NECA. The reaction was terminated by filtration with GF/B filters. Filters were placed in scintillation vials containing 5 ml of Hydrofluor scintillation buffer and counted using a PerkinElmer Tricarb 2810TR Liquid Scintillation Analyzer.
Homologous Radioligand Binding Assays
Radioligand binding assays were performed as previously described (Massink et al., 2015) . Briefly, ligand binding was measured using washed membranes from HEK 293 cells (FreeStyle 293-F, ThermoFisher, R79007) transiently expressing wild-type A 2A AR or point-mutant A 2A AR constructs. Cells were dounce homogenized (50 mM Tris HCl, pH 7.4) and centrifuged for 15 min at 30,000 g. The pellet was resuspended in assay buffer in the presence of adenosine deaminase (0.8 IU/ml, Roche) to break down endogenous adenosine. Membranes were stored in 250 ml aliquots at -80 C. Binding assays were carried out in a total volume of 0.125 ml in 96-well plates with a binding buffer with or without 150 mM NaCl as indicated (50 mM Tris HCl, 1 U/ml adenosine deaminase, pH 7.4) containing 0.5 nM [
3 H] ZM241385 (American Radiolabelled Chemicals, Inc., St. Louis, MO) or 1.0 nM [ 3 H] NECA (Perkin Elmer) for 60 min at room temperature. Membranes were harvested over 0.3% polyethyleneimine-treated, 96-well filter mats using a 96-well Filtermate harvester (Perkin Elmer) and washed three times with cold buffer (50 mM Tris HCl, pH 7.4). Filter mats were dried, wax scintillant was melted onto each filter, and radioactivity was counted in a MicroBeta2 TriLux plate scintillation counter (Perkin Elmer). ZM241385 and NECA binding affinities (K D ) for wild-type and D52
2.50 N were determined using homologous competition binding. All cell lines used arrived with a certificate of authenticity from the supplier and morphology and growth rates are constantly monitored. After thirty passages the cells are discarded. Insect and mammalian cells are periodically tested for mycoplasma using MycoAlert TM Mycoplasma Detection kit (Lonza). The cell lines used here were chosen to remain consistent with previous studies and they are well validated for these assays.
Crystallization of A 2A AR Variants
Solutions containing purified A 2A AR variants in complex with UK432097 were concentrated and reconstituted into lipidic cubic phase (LCP) by mixing in a Hamilton gas tight syringe as described previously (Caffrey and Cherezov, 2009) . The protein-LCP mixture
